Podcasts about Boston Scientific

left md branch mph abbott bundle clinical trials pacing heart failure boston scientific long term outcomes randomized clinical trial

Play Episode Listen Later Sep 3, 2026 33:54

In this episode of The Lead, host Deepak Pasupula, MD, MPH, FHRS, is joined by Zaniar Ghazizadeh, MD, and Pugazhendhi Vijayaraman, MD, FHRS, to discuss the journal article, The Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure (The HeartSync-LBBP Randomized Clinical Trial). Together, they review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure and discuss the findings of the HeartSync-LBBP randomized clinical trial. Learning Objectives Review the long-term outcomes of left bundle-branch pacing compared with biventricular pacing in patients with heart failure. Discuss the findings of the HeartSync-LBBP randomized clinical trial. Examine the clinical implications of comparing left bundle-branch pacing with biventricular pacing in heart failure. Host: Deepak Pasupula, MD, MPH, FHRS Guests: Zaniar Ghazizadeh, MD and Pugazhendhi Vijayaraman, MD, FHRS Disclosures: D. Pasupula No relevant disclosures Z. Ghazizadeh No relevant disclosures P. Vijayaraman Honoraria/Speaking/Consulting Fee: Biotronik, Boston Scientific, Abbott, Medtronic Research: Medtronic Fellowship Support: Medtronic

Novartis' Rhapsido Hits Phase 3 Goals for MS | Pharma and Biotech Daily

Pharma and BioTech Daily

Play Episode Listen Later Sep 2, 2026 5:15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the dynamic landscape of the industry, highlighting significant scientific breakthroughs, strategic partnerships, and regulatory updates that are reshaping healthcare as we know it. Novartis recently announced a major milestone with its BTK inhibitor, Rhapsido, which met its Phase 3 clinical trial goals for treating relapsing multiple sclerosis. This success is particularly noteworthy as it comes without any liver safety concerns, a common challenge for this class of drugs. The development of Rhapsido marks a promising advancement in managing neurological disorders, offering new hope for patients dealing with the debilitating effects of multiple sclerosis. However, not all developments are without challenges. Novartis and Bristol Myers Squibb have halted their CAR-T trials due to safety concerns linked to autoimmune conditions like lupus and multiple sclerosis. These pauses highlight the complexities involved in developing CAR-T therapies for non-oncological applications. At the same time, Roche and Simcere Zaiming have joined forces to develop SIM0660, a T-cell engager targeting B-cell diseases. This partnership, involving an initial payment of $75 million and potential milestones up to $1.53 billion, underscores the increasing interest in antibody-based therapies. These treatments leverage the body's immune system, moving towards more targeted modalities for oncology and autoimmune diseases. Meanwhile, drug pricing reforms continue to take center stage as the White House negotiates Most Favored Nation pricing agreements with pharmaceutical giants like Alcon and Astellas Pharma. These agreements aim to make medications more affordable by aligning US drug prices with those in other developed countries. Such policy initiatives reflect growing governmental efforts to address rising healthcare costs and improve access to essential medications. Shifting focus to vaccines, GSK has embarked on a Phase 3 trial for its mRNA-based flu vaccine. This initiative highlights the broader trend of extending mRNA technology beyond COVID-19 vaccines to tackle other infectious diseases. The adaptability and rapid production capabilities of mRNA platforms could revolutionize vaccine development and enhance our response to seasonal influenza. In cardiovascular health, Amgen's Repatha has shown a 20% reduction in mortality risk during a Phase 3 trial focused on primary cardiovascular prevention. This finding reinforces the critical role of PCSK9 inhibitors in lowering cholesterol levels and preventing cardiovascular events for high-risk patients. Similarly, Alumis faced setbacks when its TYK2 inhibitor failed to meet primary endpoints in a Phase 2 study for systemic lupus erythematosus. Despite this, promising subgroup signals suggest potential paths forward. On the regulatory front, the FDA has issued warnings to Alar Pharmaceuticals regarding unapproved promotional claims for its ketamine-based product ALA-3000. Additionally, Boston Scientific has suspended sales of its Imager II angiographic catheters due to manufacturing defects causing serious injuries. Medtronic is recalling its esophageal reflux monitoring capsule over safety issues tied to numerous injuries. These regulatory actions emphasize the critical importance of compliance with safety standards in protecting patient well-being. Industry innovation is further propelled by ongoing fundraising activities supporting cutting-edge research. Companies such as PMV Pharmaceuticals are advancing precision oncology therapies targeting p53 mutations, while Rakovina Therapeutics utilizes AI-powered platforms for cancer drug discovery. These efforts underscore the sector's commitment to addressing complex diseases through technological innovation. The exploration of novel therapeutic modalities continues with Eli Lilly's acquisition of Merida Biosciences for $2.88 billion to target autoimmune diseases by selectively degrading pathogenic autoantibodies. This acquisition aligns with broader trends toward precision medicine solutions aimed at modulating immune responses. In oncology news, Akeso's success with ivonescimab in biliary tract cancer exemplifies the potential of bispecific antibodies beyond initial indications. Meanwhile, Genentech's collaboration with DualityBio aims at overcoming resistance mechanisms in antibody-drug conjugates, promising expanded treatment options for patients resistant to existing therapies. Lastly, Labcorp's introduction of a new hepatitis D test represents a proactive step toward addressing diagnostic gaps in viral infections. Early detection remains crucial for effective disease management and improved patient outcomes. These developments collectively illustrate an industry at the forefront of innovation and strategic adaptation. As companies navigate these evolving landscapes, their focus remains steadfast on improving patient care through groundbreaking therapies while overcoming regulatory hurdles—a testament to their resilience and dedication in pursuing new healthcare frontiers.Support the show

covid-19 ai news goals white house companies hits shifting phase fda cart pharma mrna biotech roche ala eli lilly novartis medtronic gsk btk phase 3 amgen genentech bristol myers squibb boston scientific labcorp alcon pcsk9 repatha relapsing multiple sclerosis

CMV - The Virus Lurking Inside Us That Can Threaten Transplant Patients | Dr. Neil Inhaber, MD - Head, Marketed Products and Neuroscience, Global Medical Affairs, Takeda

Progress, Potential, and Possibilities

Play Episode Listen Later Sep 1, 2026 32:02

Send us Fan MailEvery year, hundreds of thousands of people around the world receive life-saving organ transplants - new hearts, kidneys, lungs, and livers that offer patients a second chance at life.But transplantation is only the beginning of the journey.Because preventing organ rejection requires suppressing the immune system, transplant recipients become vulnerable to infections that most healthy people never even notice.One of the most important - and least understood - is cytomegalovirus, or CMV.More than half of adults worldwide carry this virus, often for life, without ever knowing it. Yet in patients who have undergone organ transplantation, CMV can reactivate and become one of the leading infectious complications, threatening not only a patient's health, but also the long-term success of the transplanted organ itself.Fortunately, advances in virology, immunology, and antiviral drug development are opening new possibilities for managing this complex disease.My guest today is Dr. Neil Inhaber, MD - Head, Marketed Products and Neuroscience, Global Medical Affairs at Takeda ( https://www.takeda.com/ ).Dr. Inhaber is a physician specializing in pulmonary and critical care medicine whose career uniquely bridges frontline patient care with the development of innovative therapies. Over the past three decades, he has held senior medical leadership positions at Takeda, Shire, Boston Scientific, Baxter, Novartis, and other leading healthcare organizations, guiding clinical development, global medical strategy, and life-cycle management across rare diseases, respiratory medicine, immunology, oncology, and transplantation. Today, he helps shape Takeda's global medical strategy for some of medicine's most challenging diseases, working closely with clinicians, researchers, and regulatory agencies around the world.Today we'll discuss why cytomegalovirus remains one of the greatest infectious threats facing organ transplant recipients, what we've learned from the latest research presented at the American Transplant Congress, how new antiviral therapies are changing the treatment landscape for patients with resistant or refractory CMV, and where the future of transplant medicine and infectious disease management is headed next.Important Episode Link - LIVTENCITY® (maribavir) for Healthcare Professionalshttps://www.livtencity.com/#CMV #Cytomegalovirus #OrganTransplant #TransplantMedicine #Transplantation #Immunology #Virology #InfectiousDisease #Antiviral #DrugResistance #RareDisease #Biotechnology #Biotech #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #MedicalInnovation #HealthcareInnovation #LifeSciences #MedicalResearch #AmericanTransplantCongress #ATC2026 #Maribavir #Takeda #ProgressPotentialAndPossibilitiesSupport the show

Building an Operating System for Faster Decisions: Interview with Cala Health CEO Deanna Harshbarger

Medsider Radio: Learn from Medical Device and Medtech Thought Leaders

Play Episode Listen Later Aug 31, 2026 51:51 Transcription Available

In this episode of Medsider Radio, we sat down with Deanna Harshbarger, CEO of Cala Health.Cala Health developed the Cala kIQ® System, a prescription wearable therapy for action hand tremor.Deanna holds a degree in chemical engineering and brings more than 20 years of commercial medtech experience to Cala. Before joining the company, she held senior leadership roles at Johnson & Johnson, Boston Scientific, and Medtronic, and helped develop and commercialize technologies across interventional cardiology, neuromodulation, and diabetes care.In this conversation, Deanna shares how she empowers leadership teams to execute, building clinical evidence step-by-step, how patient observation shapes product development, and why raising capital is both a sprint and a marathon.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Deanna Harshbarger, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:34) - Deanna's journey from J&J, Boston Scientific, and Medtronic to Cala Health (08:16) - How Cala personalized therapy around each patient's unique experience (11:53) - Operating lessons Deanna carried from strategics to startups (22:27) - The unboxing interview that changed Cala's product design (29:16) - How Cala balanced feasibility studies, RCTs, and real-world evidence after its commercial launch (34:33) - Years of clinical evidence helped Cala win reimbursement for a new therapy (38:52) - The case for holding back when you're ready to commercialize (44:30) - Why fundraising is both a sprint and a marathon

Your Breaches of the Week! August 24 to August 30, 2026

The Deep Dive Radio Show and Nick's Nerd News

Play Episode Listen Later Aug 30, 2026 21:11

Carhartt, McKesson, Boston Scientific, Hasbro, and a total of 214 organization had a super week...

hasbro breaches mckesson boston scientific carhartt

Computer Talk 8-29-26 Hr 1

Computer Talk with TAB

Play Episode Listen Later Aug 29, 2026 41:35

Meta admits its Social Media is harmful to kids with $18B settlement, Meta Glasses now will stop working if you block the Recording light, Boston Scientific and McKesson Breached, Microduck Robot the next big thing? Flock OS Investigate tool getting creepy, CISA warns that Software vendors need to focus more on Secure by Design.

social media business technology design software computers recording secure cisa boston scientific 18b

Alleged TeamPCP hackers arrested, Cyberattack halts medical shipments, FBI dismantles Chinese hacking platforms

Cyber Security Today

Play Episode Listen Later Aug 28, 2026 11:21

Team PCP Arrests, Boston Scientific Shipping Halt, FBI Disrupts Chinese Hacking, CISA Cuts Scrutinized, and AI Email Summarizers Poisoned Host David Shipley covers five cybersecurity stories: Australian police, working with the FBI, arrested and charged two alleged core members of Team PCP in connection with a long-running software supply chain campaign that compromised tools like Trivy, Kiks, and LightLLM, potentially affecting over 1,000 organizations and exposing large volumes of credentials and data. Boston Scientific disclosed a cyberattack that caused network outages and disrupted global operations, halting its ability to ship devices like pacemakers and stents, with recovery expected to take weeks. The U.S. Justice Department disrupted QScan and Q2Router, platforms tied to China-linked QTFY, used to proxy intrusions against U.S. agencies and an election system. House Democrats asked GAO to assess how major workforce cuts have impacted CISA. Forcepoint demonstrated invisible-text prompt injection that fooled an AI email summarizer into fabricating invoice details. 00:00 Headlines Overview 00:29 Team PCP Arrests 02:11 Krebs Investigation 03:06 Boston Scientific Disruption 04:50 Podcast Reviews Thanks 05:07 FBI Disrupts QTFY Tools 05:50 How QScan Pipeline Worked 07:27 CISA Workforce Cuts 08:53 Invisible Text AI Poisoning 10:27 Wrap Up And Teaser

Boston Scientific Frozen by Hackers, Microsoft Wipes 171,000 Nonprofits, ATF Ransomed

Security Squawk

Play Episode Listen Later Aug 28, 2026 47:11

Your business can be taken down in three completely different ways, and only one involves a hacker. This week, a cyberattack froze Boston Scientific, the company that ships pacemakers and defibrillators to hospitals worldwide. Microsoft ended a free program, and roughly 171,000 nonprofits lost everything in their cloud storage. And a ransomware gang breached a federal agency that kept running. *Control what a disaster can reach, before it reaches everything.* Bryan Hornung, Randy Bryan, and Reginald Andre break down this week's stories for executives, owners, and operators who don't have time to follow cyber news but can't afford to be blindsided. Start with Boston Scientific. On August 25th, a cyberattack knocked out the systems this medical-device giant uses to process and ship orders worldwide, sending thousands of staff in Ireland home. The factories were never the problem. The systems that take and fulfill orders were, leaving hospitals waiting on pacemakers and stents. A group called ShinyHunters claims it stole more than 9 million records of personal data. Boston Scientific now faces two disasters: an outage it can fix and stolen data it cannot un-steal. Then there is Microsoft, where nobody got hacked. Microsoft ended a free software grant that about 400,000 nonprofits relied on. During the transition, roughly 171,000 of them lost everything in their OneDrive. One nonprofit leader had a paid renewal good through October 2026, and his data was deleted anyway. Here is what every owner needs to hear: Microsoft 365 does not back up your data. Microsoft keeps the service online, but protecting the actual files is entirely on you. Most people have that exactly backwards. We close with the ATF. The federal agency over firearms and explosives confirmed the Qilin ransomware gang hit a system holding information about the targets of its investigations, and the Department of Justice called it a "major incident." Yet the agency kept running because that sensitive system was deliberately walled off from everything else. One box got hit instead of the whole agency. Qilin is the most active ransomware brand of 2026, with victim counts up around 443 percent and North America accounting for more than half its targets. This is the playbook coming for businesses of every size. Three different villains. One lesson: you don't control when trouble arrives, only how far it gets once it does. In this episode, we discuss: • How a cyberattack froze Boston Scientific and stalled hospital device shipments worldwide • Why 171,000 nonprofits lost their data when Microsoft ended a grant, no hacker required • How the ATF survived a Qilin ransomware breach because one system was walled off • Why your cloud provider is not your backup, and what that means for your files • The one idea connecting all three: control what a disaster can reach before it reaches everything • Practical moves owners can make this week on backups, segmentation, and vendor notices Security Squawk is a weekly podcast and live stream for business owners and executives. Support the show: buymeacoffee.com/securitysquawk Subscribe | Like | Share #SecuritySquawk #CyberSecurity #BostonScientific #Microsoft #Ransomware #DataBreach #Qilin #ShinyHunters #VendorRisk #BackupStrategy #BusinessRisk #MSP

ireland microsoft north america practical frozen hackers nonprofits atf wipes onedrive ransomed boston scientific

Chinese hackers hit US agencies, Ring locks out police, Boston Scientific feels cyber pain

Cyber Security Headlines

Play Episode Listen Later Aug 27, 2026 6:10

China contractor hack hits US agencies Ring throws away the key Boston Scientific feels cyber pain Get the show notes here: https://cisoseries.com/cybersecurity-news-august-27-2026/ Huge thanks to our episode sponsor, ThreatDown SMBs face enterprise-level, AI-driven threats every day, often sacrificing robust security in favor of operational agility. You don't have to choose between moving fast and staying protected. ThreatDown bridges the expertise gap, replacing fragmented, legacy tools with proactive, 24/7 MDR that scales with your business. ThreatDown. Enterprise-grade defense. Built for businesses like yours.

ai china pain chinese police built ring hackers enterprise cyber agencies locks mdr boston scientific

Revolution Medicines FDA Win: RAS Inhibitor Approved | Pharma and Biotech Daily

Pharma and BioTech Daily

Play Episode Listen Later Aug 27, 2026 5:13

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into today's top stories, where pioneering advancements and strategic shifts are reshaping how we understand and treat complex diseases. In recent developments, Akeso's PD-1xVEGF bispecific antibody ivonescimab is making waves beyond its initial use in non-small cell lung cancer. The successful completion of a Phase 3 trial for biliary tract cancer marks a pivotal moment, suggesting broader applications of this dual-targeting therapy. Ivonescimab's mechanism—enhancing immune response while inhibiting tumor angiogenesis—could significantly improve patient outcomes across various cancers. However, questions about its efficacy continue to prompt careful scrutiny as it challenges existing treatment paradigms. Regulatory dynamics are equally compelling, with the FDA undergoing potential restructuring under President Trump's nominee for commissioner. The creation of two new deputy commissioner roles is speculated to enhance oversight and accelerate drug approval processes. Such changes are crucial as the FDA navigates increasing demands for rapid evaluations amidst complex pharmaceutical landscapes. Meanwhile, Teva Pharmaceutical Industries finds itself under a competition probe in Turkey, highlighting global antitrust challenges within the industry. As Teva juggles its dual role as a generics leader and an innovator, this scrutiny underscores the delicate balance of maintaining market dominance while adhering to fair competition laws. On the safety front, Baxter International has initiated recalls of two medical products due to particulate contamination concerns. This action underscores the critical importance of rigorous quality control in safeguarding patient trust and safety. Similarly, Vitruvias Therapeutics has recalled thyroid tablets labeled "superpotent," emphasizing precision's vital role in pharmaceutical manufacturing. Eli Lilly is expanding its focus on obesity treatment through Medicare access campaigns for GLP-1 receptor agonists. By targeting older adults, Lilly aims to address obesity as a chronic condition requiring sustained intervention, potentially enhancing health outcomes for millions. Public health remains a pressing concern as Pennsylvania reports its first measles-associated deaths in decades amid rising nationwide cases. This situation highlights the ongoing need for robust vaccination campaigns and public health strategies to combat vaccine-preventable diseases effectively. Cybersecurity is also at the forefront, with Boston Scientific experiencing disruptions from a cyberattack. This incident reflects a broader trend affecting medtech firms globally, underscoring the necessity for robust cybersecurity measures to protect sensitive data and ensure uninterrupted healthcare services. Strategic collaborations continue to drive innovation. SK Biopharmaceuticals' $795 million deal with Biohaven Pharmaceuticals aims to accelerate epilepsy therapy development targeting KV7 ion channels. Such partnerships exemplify how strategic investments can expedite drug development timelines and bring promising therapies to market faster. LabCorp's launch of a new hepatitis D test represents an advancement in diagnostic capabilities, aiming to identify patients with severe viral infections earlier, potentially leading to more timely interventions and better management of complications. Shifting our focus back to oncology, Revolution Medicines has achieved FDA approval for daraxonrasib, a RAS inhibitor targeting metastatic pancreatic cancer. With compelling data presented at ASCO, this approval signifies a breakthrough in treating RAS mutations—a challenging target implicated in many cancers. The drug's direct inhibition of mutated KRAS proteins disrupts cancer cell proliferation pathways considered "undruggable" until now. The implications are profound: daraxonrasib not only offers hope to patients with limited options but also sets new benchmarks for future RAS-targeted therapy development. It highlights precision medicine's growing trend—tailoring treatments based on genetic profiles to enhance effectiveness while minimizing side effects. In another significant advancement, Jazz Pharmaceuticals' Ziihera (zanidatamab) has been approved by the FDA as a first-line HER2-targeted therapy for gastroesophageal adenocarcinoma. This bispecific antibody represents a promising new class of treatment, enhancing options for patients with this aggressive cancer type and underscoring personalized medicine's importance in oncology. As we conclude today's update, these developments showcase how scientific breakthroughs, regulatory adaptations, and strategic collaborations collectively shape the future landscape of drug development and patient care globally. The industry remains dynamic as it navigates complexities while striving for innovative solutions that promise better health outcomes across diverse medical conditions. Stay tuned for more updates on Pharma Daily as we continue bringing you insights into the ever-evolving world of pharmaceuticals and biotechnology.Support the show

donald trump public revolution pennsylvania turkey shifting phase strategic fda cybersecurity medicare approved glp pharma regulatory biotech ras medicines eli lilly asco boston scientific her2 inhibitor kras labcorp jazz pharmaceuticals baxter international teva pharmaceutical industries

The feds flip the script.

The CyberWire

Play Episode Listen Later Aug 26, 2026 32:31

The U.S. disrupts a Chinese hacking operation blamed for intrusions at several sensitive government agencies. CISA says more than 100 water systems were targeted in July. Attackers exploit a critical Gitea flaw, while malicious pages masquerade as Cloudflare verification screens. Cyber insurance claims get costlier, and AI agents break out of their sandboxes. Boston Scientific battles a cyber incident. Plus, a new standard tracks AI agent activity, criminals target stolen iPhones, and an alleged money mule is charged in a $7.5 million scam. Our guest is Stephen Hilt, Sr. Threat Researcher at TrendAI, on the risks facing data centers. Some breach data doesn't quite measure up. Remember to leave us a 5-star rating and review in your favorite podcast app. Miss an episode? Sign-up for our daily intelligence roundup, Daily Briefing, and you'll never miss a beat. And be sure to follow CyberWire Daily on LinkedIn. CyberWire Guest On today's Industry Voices, we are joined by Stephen Hilt, Sr. Threat Researcher at TrendAI discussing the cybersecurity risks facing data centers and the thousands of internet-exposed industrial control systems that could leave them vulnerable to attack. And if you enjoyed this conversation, be sure to check out the full interview here. If you'd like to hear more on this topic from TrendAI, you can check out this recent episode of the AI Security Brief podcast that focuses on data center security. Guest Mark Houpt, CISO at DataBank, joined hosts Johnny Hand and Dustin Childs to explain why securing the AI era starts with protecting the physical data centers that power it—and why proven security fundamentals still matter against rapidly evolving threats. AI Security Brief podcast publishes every other Thursday on the N2K CyberWire network. Subscribe today! Selected Reading China-sponsored hacking platforms seized by US, Justice Department says (Reuters) CISA: Over 100 Internet-Exposed Water Systems Targeted in July Cyberattacks (SecurityWeek) Hackers now exploit critical Gitea flaw in code injection attacks (Bleeping Computer) Hackers abuse npm mirrors to host phishing redirect pages (Bleeping Computer) Average Cyber Insurance Losses Increase Despite Fewer Claims (Infosecurity Magazine) VMs won't contain cyber-capable agents (Trail of Bits) Boston Scientific hit by cyberattack, global operations affected (Reuters) Linux Foundation Introduces TRACE Standard for AI Runtime Evidence (Infosecurity Magazine) AnonyMousKIT PhaaS uses voice AI agents to phish iPhone passcodes (Bleeping Computer) Indian man who fled US arrested on charges he helped scammers siphon $7.5 million from the elderly (The Record) Trump signs memo to help drastically boost US commercial space launches (Reuters) A Cautionary Tale About Data Breach Claims, Verification and Carhartt (Troy Hunt) Share your feedback. What do you think about CyberWire Daily? Please take a few minutes to share your thoughts with us by completing our brief listener survey. Thank you for helping us continue to improve our show. Want to hear your company in the show? N2K CyberWire helps you reach the industry's most influential leaders and operators, while building visibility, authority, and connectivity across the cybersecurity community. Learn more at sponsor.thecyberwire.com. The CyberWire is a production of N2K Networks, your source for strategic workforce intelligence. © N2K Networks, Inc.

ai chinese iphone sr trail cyber reuters feds justice department verification cloudflare attackers ciso flip the script cisa boston scientific daily briefing databank cyberwire gitea dustin childs

ECB-bobo wil de rente verhogen. Meerdere keren!

Beurswatch | BNR

Play Episode Listen Later Aug 26, 2026 22:52

We hebben het deze aflevering over de vrienden van de Europese Centrale Bank. Over Isabel Schnabel om precies te zijn. Zij zegt dat de rente al in september omhoog moet. De rente zou dan naar 2,5 procent gaan. Want zegt ze: de Europese economie groeit harder dan gedacht. En de inflatie blijft stijgen. Het is vooral de oorlog in het Midden-Oosten die energie- en voedselprijzen flink omhoog hebben geholpen. Uiteindelijk zou de rente zelfs naar 3 procent gaan, denken kenners. We kijken wat de renteverhoging (of verhogingen) betekenen voor de beurs. Of de Fed dan óók verhoogt. En wat dat met jouw aandelen doet. Hebben we het ook over Bill Gates. De man bekend van Microsoft en inmiddels ook de Epstein-files. Die wil een soort van AI-gezant worden. Hij wil (namens de VS) met Xi Jinping gaan onderhandelen over regels op het gebied van kunstmatige intelligentie. Tot slot ook aandacht voor Dolly Parton. Queen of Country én geniaal zakenvrouw. Te gast: Martine Hafkamp van Fintessa Vermogensbeheer BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Je hoort hem ook in de BNR-podcast Moerdijk: dorp van de rekening. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en is redacteur bij de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie.See omnystudio.com/listener for privacy information.

ai china disney japan elon musk microsoft wall wall street manhattan louisiana amsterdam cybersecurity bill gates mark zuckerberg spacex epstein chips fed openai dolly parton nvidia songwriter index elvis presley nasdaq technologie whitney houston reuters nederland xi jinping zijn hij data centers tot anthropic filters nederlandse zij dow starship rente bobo dow jones hebben softbank schulden microplastics sinds ecb royalties keren europese kinderen vraag asml pacemakers uiteindelijk christine lagarde verenigde staten amsterdamse small cap indices zweden bedrijf sp500 twente abn amro bedrijven i will always love you boston scientific winst investeren hacken midden oosten bnr saxo hollandse koers masayoshi son meerdere s&p500 verslaving beleggen omzet ahold beurs stents inflatie sociale media rechtszaak investeringen chinese president kunstmatige intelligentie s&p aandelen toezicht beleggers verdienmodel investeerders aex ruimtevaart europese centrale bank advertenties financieele dagblad isabel schnabel obligaties moerdijk damrak auteursrechten

Börsenradio Schlussbericht, Mi., 26.08.26: Zwischen Inflationssorgen und Nvidia-Fieber: SAP fällt, Abercrombie hebt ab.

Börsenradio to go Marktbericht

Play Episode Listen Later Aug 26, 2026 16:04 Transcription Available

DAX knapp im Plus, aber deutlich unter Tageshoch: Vor den Nvidia-Zahlen und nach hartnäckigen US-Inflationsdaten bleiben Anleger vorsichtig. SAP fällt nach UBS-Abstufung, Boston Scientific nach Cyberangriff. Abercrombie & Fitch überrascht mit starken Zahlen und höherer Prognose. Siemens Energy stellt sein Industriegeschäft neu auf, KNDS startet die Patria-Produktion.

zwischen nvidia zahlen sap fitch abercrombie prognose hebt fieber anleger boston scientific indus sfc cyberangriff inflationssorgen knds us inflationsdaten

Knowing When to Pivot Without Starting Over: Interview with ABK Biomedical CEO Michael Mangano

Medsider Radio: Learn from Medical Device and Medtech Thought Leaders

Play Episode Listen Later Aug 25, 2026 51:54 Transcription Available

In this episode of Medsider Radio, we sat down with Michael Mangano, President and CEO of ABK Biomedical. ABK's Eye90 is an investigational Y90 radioembolization device for treating unresectable liver cancer.Michael brings over 30 years of medical device experience, including 15 years at Boston Scientific in commercial and international leadership roles. He previously served as CEO of ReShape Medical and as President of the Americas for Sirtex Medical, scaling regional revenues from $34 million to over $130 million.In this interview, Michael discusses the thinking behind ABK's pivot into Y-90 radioembolization, what it takes to execute a 120-patient pivotal trial while retaining ownership over the clinical function, how to build capabilities that competitors can't quickly catch up to, and why the player-coach culture gives startups an execution advantage.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Michael Mangano, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:09) - Michael's journey from Boston Scientific and Sirtex to leading ABK Biomedical (04:54) - Why Michael pivoted ABK from embolization to radioembolization as soon as he joined as CEO (09:24) - How ABK reimagined Y-90 around physician control and patient-specific dosing (21:08) - What a functioning player-coach culture looks like inside a startup (27:26) - Lessons learned from a complex 120-person pivotal trial and how ABK remained the face of the study while partnering with a CRO (37:13) - How ABK is building advantages competitors can't easily replicate (42:50) - Michael's framework for choosing the right investors

Klaus-Michael Kühne ist tot. China pusht KI. Boston Scientific zu günstig? Porsche macht KI mit Indien.

OHNE AKTIEN WIRD SCHWER - Tägliche Börsen-News

Play Episode Listen Later Aug 25, 2026 12:44

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Mit eigenem KI-Chatbot, der dir alle Fragen rund ums Investieren beantwortet. Alle weiteren Infos gibt's hier: scalable.capital/oaws. KI-Chips unter Druck. Goldpreis auf Hoch seit Mai. Alibaba sammelt 10 Mrd. $ für KI. YMTC plant IPO. Xpeng baut Roboter-Sparte auf. Trump will 50% Autozoll auf Kanada. Porsche zahlt 1,3 Mrd. € an Tata für KI. NVIDIA will Perplexity-Anteil. Aktie von Boston Scientific (WKN: 884113) hat 50% verloren. Die zwei Wachstumsmotoren Farapulse und Watchman schwächeln. Aber der CEO kauft für 9 Mio. $ eigene Aktien. Turnaround oder Falle? Klaus-Michael Kühne ist verstorben. Sein 49 Mrd. $ Imperium liegt in einer Stiftung. Wie kam es dazu und wie geht es jetzt weiter? Kühne + Nagel (WKN: A0JLZL), Hapag-Lloyd (WKN: HLAG47), Lufthansa (WKN: 823212), Brenntag (WKN: A1DAHH). Wie geht's weiter? Diesen Podcast vom 25.08.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dose #27: Beyond Capacity: How CDMOs Can Win the Future with Robert Hayes (Hayes Healthcare)

Supply Chain Wizard for Pharma

Play Episode Listen Later Aug 24, 2026 40:40

In this episode of SCW for Pharma, host Evren Ozkaya welcomes Robert Hayes, Founder and Principal of Hayes Healthcare. Drawing on more than 30 years of experience across pharmaceutical manufacturing, MedTech, supply chain, commercial leadership, and executive management, Robert shares the lessons that took him from the shop floor to leading a publicly traded company.The conversation begins with Robert reflecting on his manufacturing roots at companies including Fresenius Kabi, Boston Scientific, Cardinal Health, and Amcor. He explains how hands-on experience in high-volume manufacturing and pharmaceutical quality helped him build the technical expertise and problem-solving skills that later enabled his transition into business development and executive leadership.Evren and Robert then discuss how the COVID-19 pandemic reshaped pharmaceutical manufacturing and supply chains. They explore how exposed vulnerabilities accelerated reshoring efforts, increased investments in domestic manufacturing capacity, and prompted companies to rethink long-term supply chain resilience.Looking ahead, Robert identifies home-based therapies and drug delivery devices, such as auto-injectors, as one of the next major opportunities and challenges for the industry. As treatments increasingly move closer to patients, manufacturers and CDMOs must develop solutions that combine reliability, scalability, and ease of use.The discussion then turns to the future of CDMOs. Robert argues that capacity and quality are no longer enough to stand out. Instead, CDMOs must become strategic partners by understanding their customers' products, strengthening risk management, and helping pharmaceutical companies solve broader operational challenges. They also discuss how digital transformation, connected data, and AI can improve agility, quality, and decision-making, enabling CDMOs to deliver greater value in an increasingly competitive market.Evren and Robert conclude the conversation by emphasizing the importance of building strong technical foundations, staying close to customers, and embracing continuous learning. Robert encourages the next generation of leaders to pursue work they are passionate about while remaining adaptable in a rapidly evolving pharmaceutical industry.

covid-19 founders ai drawing healthcare principal capacity dose pharma medtech boston scientific cardinal health evren scw robert hayes cdmos

Hedging exposure in this volatile market

Investing Experts

Play Episode Listen Later Aug 20, 2026 35:28

Michael Kramer from Reading The Markets shares why it's important to understand market direction, implied volatility and option positioning (1:00) Why he's focused on healthcare and stocks like Illumina (7:40) Boston Scientific and Zoetis - lessons learned (15:20) Macro winds mattering less (19:00) Be wary of passive investing (30:15)Episode transcriptsShow Notes:Life After Mag 7For full access to analyst ratings, stock quant scores and dividend grades, subscribe to Seeking Alpha Premium at seekingalpha.com/subscriptions

investing healthcare trading stocks exposure macro hedging boston scientific illumina volatile market zoetis michael kramer

The Lead Episode 165: A Discussion of Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (The CLOSURE-AF Trial)

speaker left therapy md medical closure medtronic atrial fibrillation mbbs boston scientific

Play Episode Listen Later Aug 20, 2026 32:39

In this episode of The Lead recorded at HRS2026, host Danesh Kella, MBBS, FHRS is joined by Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS to discuss the journal article, Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (The CLOSURE-AF Trial). Together, they review the study findings comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation and discuss the potential implications for clinical practice. Learning Objectives Review the design and key findings of the CLOSURE-AF Trial comparing left atrial appendage closure with medical therapy in patients with atrial fibrillation. Discuss the comparative considerations of left atrial appendage closure and medical therapy for the management of atrial fibrillation. Examine the potential clinical implications of the CLOSURE-AF Trial for treatment decision-making in patients with atrial fibrillation. Host: Danesh Kella, MBBS, FHRS Guests: Jeffrey S. Healey, MD, FHRS and Fred M. Kusumoto, MD, FHRS Disclosures: D. Kella Honoraria/Speaking/Consulting Fee: Zoll Medical Corporation, MBW Spectrum J. Healey Honoraria/Speaking/Consulting Fee: Boston Scientific, Servier Research: Pfizer, Boston Scientific, Medtronic, Inc. Speakers' Bureau: Bristol-Myers Squibb F. Kusumoto No relevant disclosures

140 ON, OFF, and Dyskinesia: The Medication Roller Coaster

parkinson roller coasters medications dbs boston scientific ospina deep brain stimulation dyskinesia

Play Episode Listen Later Aug 18, 2026 27:02

After living with Parkinson's for 10 years, I still struggle to recognize when I'm experiencing OFF time. And dyskinesia? I never quite know when it will happen or why. I'm sure I'm not alone. So, as part of our "Dr. Ospina Explains" series, I asked Dr. Ospina to break down the terms we hear so often in Parkinson's: ON, OFF, dyskinesia, dystonia, and more. She walks us through the medication roller coaster—what it looks like, why it happens, and how it can change over the years. She also explains how to tell the difference between OFF symptoms, dyskinesia, and dystonia, and why it's important to pay attention to more than just movement. Non-motor symptoms can also fluctuate with medication and may even signal an approaching OFF period before motor symptoms appear. This is an episode you may want to bookmark and come back to. Understanding these differences can help you recognize what's happening in your own Parkinson's journey—and, ultimately, better communicate with your care team about how symptoms are affecting your quality of life. Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

The Benefits of Sunshine and UVB Light with John MacMahon! 1020

Boundless Body Radio

Play Episode Listen Later Aug 10, 2026 57:05

Send us Fan MailJohn MacMahon is a serial entrepreneur specializing in early-stage product development. Beginning with Kerberos Proximal Solutions, he has led and/or founded numerous medical device startups in the vascular field. John was the COO for Maya Medical and led their transfer of manufacturing from the US to Ireland. He was also the General Manager for Europe for Claret Medical (acquired by Boston Scientific).Presently, John is the CEO and co-founder of CytoKind, where they are expanding the research on the benefits of increasing exposure to narrow-band UVB light (NB-UVB), and is the CEO of Mitre Medical. John is an active mentor for entrepreneurs from Stanford BioDesign, Enterprise Ireland, and the Kauffman Foundation.He received his Bachelors in Physics at the University of California, Santa Cruz, and graduate studies in both electrical and biomechanical engineering at Stanford University (MS EE).Our skin is specifically tuned to absorb NB-UVB light, which starts a natural cascade of actions that calms the immune system and reduces inflammation for better health. In psoriasis, for example, NB-UVB performs as well as Humira clinically, and outperforms it in patient quality of life satisfaction.Find John at-https://cytokind.net/Find Boundless Body at-myboundlessbody.comBook a session with us here!

From the Army Commander to the CDMO Corner Office

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Aug 7, 2026 49:45

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Denis Johnson, Chief Executive Officer at Grand River Aseptic Manufacturing. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denis, covering: What his time in the military and the CDMO industry have in common Why he is passionate about operations, and why operational excellence is the real product CDMOs deliver His decision to leave a successful leadership role at Catalent and move to the customer side of the industry Realising his ambition of becoming a CDMO CEO, and why sterile fill finish remains such an attractive area of the market The case for staying focused in small molecules rather than trying to become a “Swiss Army knife” provider Why sterile manufacturing continues to be one of the biggest pain points in pharma launches and commercial supply Denis Johnson brings extensive life sciences leadership and manufacturing experience to his role as CEO, including significant prior sterile fill-finish experience. He has led operations and commercial senior leadership roles in the biologics, pharmaceutical, and combination devices for over 25 years. Before being appointed CEO at Grand River Aseptic Manufacturing, his prior roles include Head of Global Manufacturing and Technical Operations at Biogen as well as leadership roles at Catalent, Boston Scientific and Johnson & Johnson. He started his career in the U.S. Army managing logistics and operations. Denis earned a B.S. in Economics from the University of Wisconsin Madison and an MBA from the University of South Carolina. Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

ceo university head market army mba economics south carolina chief executive officer commander denis wisconsin madison molecule swiss army biogen boston scientific corner office denis johnson technical operations catalent raman sehgal

Dave Rosa | CEO, NeuroOne | Advancing Electrode Technology for Neurological Disorders & Passion for Helping Others

The Leading Difference

Play Episode Listen Later Aug 7, 2026 33:01

Dave Rosa shares how a lifelong drive to help others and his own health challenges led him into 32 years across orthopedics, cardiovascular, and neuro. Dave walks through his path from early marketing roles to becoming a CEO, and explains the innovation behind NeuroOne's electrode platform designed to combine diagnosis and treatment in a single procedure—starting with epilepsy, expanding to trigeminal neuralgia, and now targeting lower back pain. He also discusses early work using the same technology for precise drug delivery to the brain, including a program focused on glioblastoma. Dave closes with leadership lessons on vision, culture, learning from mistakes, and giving back. Guest links: https://nmtc1.com/ | https://www.linkedin.com/company/n1mtc/ Charity supported: Opportunity International Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com. PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical EPISODE TRANSCRIPT Episode 086 - Dave Rosa [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guest, Dave Rosa. Dave is an entrepreneur with three decades of experience in the medical device industry, spanning a variety of technologies and products. In addition to CEO roles with early-stage medical device companies, Mr. Rosa's background also includes senior roles with C.R. Bard Inc., Boston Scientific Inc., and St. Jude Medical, where his responsibilities included marketing, product development, and business development. He has been named as an inventor on multiple medical device patents, serves on seven corporate boards, and has raised 200 million in the capital markets. Well, Dave, thank you so much for being here today. I am absolutely delighted to have you on the show. [00:01:33] Dave Rosa: Well, thanks for having me. [00:01:34] Lindsey Dinneen: Yeah, of course. I would love, if you wouldn't mind, by starting out and just telling us a little bit about yourself, your background, and what led you to medtech? [00:01:45] Dave Rosa: Yeah. So, born and raised in a small town called Richport, Pennsylvania, outside of Philadelphia. And really was in love with the medtech industry from the time I was much younger. So I, I have been in medtech now, it's going on 32 years and that's everything from large medical device companies to, to startup companies. I've been in so many different areas of medtech. I've been in orthopedics, cardiovascular, and I mean everything involving the heart, I've been in it in some way, shape, or form, a-a-as well as neuro, which is what I'm in now. And, and I think, you know, why did I get into medtech? I think this all goes back to when I was a little kid. You know, I, I was the little kid that was walking street people to my house and bringing them into my home for my mom to make a meal. I don't know that she always appreciated that me doing that, but, but there, there were more than enough times where she sat me down and I was maybe only four or five years old, and she's like, "Honey I, I, I know you wanna help people, but you can't bring everyone home." And I was like, "Oh, oh, you know, okay, Mom." Of course, until the next time. But, you know, I think it started at an early age and, and really has carried through you know, the rest of my career [00:03:07] Lindsey Dinneen: Yeah. Yeah, okay. So you've always been interested in helping people, and you've had a really nice variety of experiences within medtech. But tell us about your path from that early just interest and care in, in people and their wellbeing, to perhaps your educational journey and maybe, like, the first little bit of your career that led you to where you are now. [00:03:32] Dave Rosa: Yeah. So, in high school I was involved in sports and, and even prior to high school, and I had so many physical issues. So I had initially a shoulder problem that was I'll, I'll say pretty complicated, at least back in those times. And what I found is by the time I got to college, and, you know, I'm still trying to figure out what I wanna do with with my life and what career I wanna take. I, I was actually in chemical engineering, but came, came to the conclusion that I hated chemistry, which, which didn't help things out. And, and I really knew, you know, my, my passion was on the medical side, and a lot of it, you know, was driven because of my own issues, my own shoulder issues, because it really put a damper on, you know, any, any potential I had at especially playing baseball. So, so, i- in college, I went to Drexel University, there really wasn't a course for biomedical, undergraduate biomedical engineering that was, like, a graduate program. And, you know, I, I decided that I would take courses in electrical engineering and a program called commerce and engineering, which kinda merges both the business and engineering side of the equation. So, I, I actually started out not in medical. I was in electrical engineering, and I was probably one of the worst electrical engineers working at Westinghouse at the time. And I remember one of the managers saying to me, he's like, "You know, all, all the other engineers and marketing people really like working with you. Why is that?" And I said, "I, I really don't know other than, you know, I've always been a passionate person about whatever I'm doing." So, you know, so at that point, I started thinking that engineering was not the path for me, that you know, that I was really more, much more passionate about medical because it was impacting my life with my shoulder. And then by that time, you know, my knees and everything else started to go as well. But I graduated with a degree in commerce and engineering, and then after working a few years in electrical engineering for Westinghouse Electric I just started knocking on doors because I, I really-- my passion was, you know, helping others, and I wanted to be involved in an area that might help me being orthopedics. So that, that's kinda how I got my first job, knocking on doors, and Stryker Instruments decided they would take a chance on me, and that, that was kind of the beginning. [00:06:12] Lindsey Dinneen: Very nice. And so when you found medical device, was it this really exciting moment of realizing that it could marry your interests in engineering and your desire to help people? Was that like just this cool moment of going, "Oh, wow, like I, I can do both"? [00:06:31] Dave Rosa: Yeah. I, I, you know, I remember actually praying about this, like, "What am I supposed to do?" Like, you know, and, and "How do I go about this?" And I don't know, you know, it, it, it brought back some memories you know, of when my father was you know, was at the end of his life, and he was this stern Italian man. Never, you know, never-- there, there was no discussion about feelings or anything like that. It was like, "You do what I tell you to do. You, you talk when I tell you to talk. Otherwise, you know, you say nothing." So my, my dad's literally on his deathbed, and he says to me, "You know, I, I really wanna thank you, son, for taking care of your mother and I all these years with, you know, medical decisions." And he said, "You know, you, you always were helping people from the time you were a little boy." And it actually stunned me that my dad, who never appeared to be paying attention to anything regarding me, was like, "Hey, you know, you, you know, you really cared about helping people, not just us, but, you know, this, this goes back to the beginning for you." So it, it was also more of a reinforcement of like, "Yeah, I've, I've really gotta be in medtech, and I'm gonna start with, you know, how I can help my own issues and/or, you know, family's members' issues that they may have." [00:07:52] Lindsey Dinneen: Mm-hmm. Yeah. Yeah. I think sometimes we don't realize the impact that we're making at the time and being able to just do what we feel is right and, and what we know helps others can actually make an impact, and then hopefully we get those opportunities like you got with, with your father to s- realize eventually, "Oh, okay, yeah, I, I am, I am on the right path doing, doing the right thing at this time." So yeah, it's great to have those moments of reinforcement, but. [00:08:26] Dave Rosa: And if you fast-forward, you know, to something again, just more reinforcement, although it's much later in my career and I've had other moments like this, but this was just last month. I was at, at a memorial service for one of the physicians that used our product to treat a, a young lady, she was 17 years old at the time for epilepsy. And so the doctor that performed a procedure on her had a tragic accident, passed away, and we were all at this memorial service for him. And the father along with the mother and, and this young lady who's now in college, they came up to me you know, we were, you know, just chatting about how unfortunate the situation is. And when I got ready to, you know, go back to the service he said to me "Sir, I, I just wanna thank you for giving my baby girl her life back." And I mean, those kinds of things, when, when people say those things to you, and like I said, it's happened more than once, and, and it's because of something, you know, that you've you know, committed the, the company to accomplishing, and then you see results like this, there's nothing more rewarding than that. [00:09:39] Lindsey Dinneen: Yeah, of course. Yeah. Thank you for sharing that. So, all right, so in fast-forwarding a little bit you, you started in medtech with Stryker, and then what gave you-- and, and there's probably maybe some things in between-- but what gave you the the idea for what you're doing now? And can you just take us along that journey from starting out in medical device to where you are now, including that just pathway to even, to even higher roles in leadership and that learning curve as well? [00:10:12] Dave Rosa: Yeah, that's-- boy, that's a long story when you've been in it for 30-some years. You know, I, I started out in marketing. I always liked the interaction between customers, meaning, you know, physicians, patients, when, you know, we had the opportunity to, you know, to speak to the patient. And then, you know, I, I I would like to think that maybe some of my decision-making and, and some of my ideas, you know, led to success in some of these companies. And you know, I think upper management you know, wa-was able to identify that I might have some of the, the qualities that they were looking for really in the next generation of leaders. And this goes back to you know, my, my first job in the cardiovascular industry. Gosh, this was in 1995, so, about 30 years ago with Boston Scientific. And I was able to go from a Product Manager to a Director of Marketing. And I was there for a total of about four years, and I, I really enjoyed the strategic part of the job, and I, I wanted to be more involved in that. And I got an opportunity to go to a startup to run sales and marketing also in the cardiovascular space. And that was a, a great experience because, you know, in smaller companies, and this, by the way, was my first opportunity in a smaller company, you know, you, you have to wear a lot of hats. And I liked, I always liked to be more hands-on and still am, to be honest, and, you know, th-this gave me an opportunity to really you know, get involved in more than just what the job detail or the job description called for. And, you know, the-these things all, sometimes, you know, require some luck but definitely, you know, the right timing. And an opportunity in the startup company that I left Boston Scientific for became available at the CEO level, and the the investors-- the company was funded by venture capitalists-- met with me and said, "You know, we, we think you can take the company to the next level." And I think that was back in 2003, and pretty much been a CEO ever since then. But I, you know, I think a lot of the success comes from and confidence from, you know, the, the hiring companies. I, I think what people notice about me is my passion, my, my commitment, and, and probably the fact that you know, I, I think one of the things I'm strong with is developing a, a, a vision. I mean, that's, that's something that I think is really critical with leaders is that you, you've gotta develop a vision for the company, a strategy for the company so that others can understand what the goals are. So that, that's kinda my path. It's, you know, it's, it's I would say every four to five years I've had an opportunity to either start a company or run a company. And then NeuroOne, which is, you know, my current company, I was actually retired when I was approached by a few individuals who had this idea. And what started out as me just, you know, helping them turned into "Gosh, we would love you to run the company." And I really thought there was an opportunity there, you know, to help people who suffered from these neurological disorders, primarily brain-related disorders. But, you know, that, that vision has kind of expanded beyond just the brain into other areas of the body. [00:13:56] Lindsey Dinneen: Wow. Yeah. Okay, yeah. I appreciate you sharing more about your journey. I love the fact that you're both an engineer and you have this creative side with marketing, and you're able to marry all that together. That's, that's really cool, and gives you such a unique perspective on, you know, I would say product development and then commercialization. But okay, so let's talk about your company now, and what are you excited about? What are some of the innovations coming out of it? You mentioned that it sort of s- it started in one place and one focus, and now we get to see it expanding. And so I'd just love to hear all about your company as well. [00:14:33] Dave Rosa: Sure. So, we started out with the intention to develop this electrode technology, and initially it was primarily to be used for brain-related procedures for patients, initially at least, that were suffering with epilepsy. And this, this technology, the, the idea was "Let's combine functions with this" in that it, it, it would have the ability to perform a diagnostic function. And for these patients, the diagnostic function was finding the area in the brain that was triggering these issues. And then once you were able to accomplish that, then using the same device, destroy that brain tissue that was causing the problem in an effort to eliminate the seizures that patients were having. So that, that's kind of where we started. We, we are selling that technology. We have a distribution partner, Zimmer Biomet, that is our exclusive distributor for that technology, and we've had great success in treating patients. You know, the story that I told about the father you know, who thanked me for getting his daughter's life back, that's what that technology is used for. And the-- really what patients had to face before this technology was available is they would have to have a very invasive surgery just for the diagnostic part of the procedure. So the part where you're just trying to identify the problem area, that was one surgery. And we're, we're talking about, you know, drills that are drilling holes, you know, through the skull with these devices being placed in the brain. And then once that part was done, the patients would go home, and they would be scheduled for a follow-up procedure where they would have to come back again, have an invasive procedure in-into the brain, and then that, that second procedure would be the one where they would eliminate or destroy the problematic brain tissue. So if you're a patient, two invasive surgeries, two hospitalizations, two separate devices, and we said, "Why can't you do it with one?" And, and that's, that's where we are. We then more or less leveraged that technology to treat a a condition called trigeminal neuralgia, which is this excruciating facial pain that patients will experience. And it, there-- it's very well known to carry a a high rate of suicide because of how painful this condition is. But we were able to leverage the same system and provide the neurosurgeon you know, with, with a very unique tool to treat that condition. We also-- what I'm also excited about is these-- the, the same platform we're using now to develop technology to treat lower back pain. There's different types of lower back pain. We, we happen to be focusing on two. One that involves issues with the basivertebral nerve, which is a l- a nerve in the lower spine. And then the more common back pain where you have pain that's traveling down the leg, that's sciatic nerve pain. So we've been able to use the same electrode to to develop technologies, unique technologies that would be able to treat that condition. And then finally, drug delivery. These electrodes have a hollow center and we've been able to demonstrate in animals so far that not only can you use it for diagnostics and stimulating through, but you can also deliver therapeutic agents directly into the brain, specifically where you would like to deliver them. And we, we've initiated a program to try to improve really the care for patients that suffer from glioblastomas, which are those brain tumors that carry high rates of mortality. [00:18:45] Lindsey Dinneen: Wow. Wow. Well, there is an incredible amount of innovation coming out of the company, and I'm so excited to follow along and just see all of the difference that you're gonna make in patients' lives. So gosh, first of all, thank you for what you're doing. I, I'm curious, you know, you, you've had such a great career and so many different opportunities to grow into more and more leadership roles. And I, I'm wondering, first of all, what your own leadership philosophy is, sort of as a whole, and then maybe some examples of both good and not as ideal leadership that helped to shape it. [00:19:28] Dave Rosa: Yeah. So, I mean, for me, you know, the, the people that I've always looked at that I think are great leaders are, are those people that can communicate a vision and, and really instill a passion to inspire others in the company to have the same sort of passion to achieve this, this overall vision or this overall strategy. And, you know, I, you know, I-- there, there have been clearly people that I've worked for in my life that I've said, "Gosh you know, they, they really were inspirational to me to be better," not just I would say as a leader, but just more effective overall. And, you know, I, I, you know, I, I-- when I look at my own areas that when I think about leadership and what I can do to, to be more effective, you know, I some of the areas that I've personally looked at i- are things that can make the company more efficient. And artificial intelligence is probably the one that gets, you know, the most attention today. And, and I'm looking to using it, and took a course in this actually to, to really become more efficient and help the company be more efficient in, in developing these technologies and getting them to market as, as quickly as possible. And, and I think, you know, for myself, I'm, I'm very fortunate to be surrounded by a board of directors that I look at that I think have excellent leadership qualities, and it's, it's really, you know, meeting with them on a... and, and just talking to them on a fairly regular basis, picking their mind to see how they would handle things because, you know, I'm, I'm really the, the product of stealing ideas from other people that, that I think you know, have worked well and led to the success of companies and people that they've led. So it's, it's not necessarily taking a course on leadership, but it's surrounding yourself with people that have been successful in leading groups and, you know, getting ideas from them on how to be more efficient, whether it's, you know, taking classes you know, in, in things like AI or, or just, you know, learning from their own success as to how to inspire people to, you know, to really finish the goal for whatever that goal is. [00:21:58] Lindsey Dinneen: Yeah. Yeah, and speaking of inspiring people, how do you as a leader intentionally help shape the company culture that you feel is best for, for people to thrive in? [00:22:13] Dave Rosa: Yeah. So I've, I've always been of the mindset that companies that perform the best utilize ideas that others on the team have. So there, there are, I, I'll give you a great example. I-I find that people that come from big companies have more of a mindset of execution, meaning, "So whatever the boss tells me to do, I do and I'm, I'm not gonna challenge them." So it's, it's one more of, "I, I find out what I need to do and, and and I execute that." You know, in, in our company, one of the things I try to foster is that it's okay to have a, a different opinion. We're all here, you know, trying to be successful, and none of us have all the answers. Now, there's gonna be times when we as a, a team just can't agree, and when those times occur, then, you know, the, the CEO is going to have to make the final decision because that's in my mind, that's, that's really one of the roles of the CEO. But I can tell you, in our company and in other companies I've been in, a lot of the, the great ideas on what to do, you know, have really come from others. They haven't, they haven't come from me. I'm-- I may be setting the overall vision, but sometimes, you know, you, you take a small detour because someone in the group who wasn't afraid to speak up, you know, has an idea or a thought that you know, makes the, the outcome more successful, whether it's shortening the time or coming up with a different idea, a different concept. I constantly try to hi- hire people that have skill sets that I don't have. So for example, I recently, within the last two months hired a guy that had great experience in the pharma space and really how to navigate that space and understands the, the therapies that are out there. And in a very short period of time you know, I realized, "Gosh, this guy, you know, knows so much more than I know and I'm gonna learn a lot from him." So I think it's, it's, it's really empowering the people that you hire, you know, to express what their thoughts and their ideas are because I don't care what CEO you're talking about, none of us, you know, have all the answers. [00:24:33] Lindsey Dinneen: Yes. And recognizing that is, is definitely, I think, key. I think a lot of the leaders that I've been talking to recently talk about exactly what you've mentioned. It's, it's recognizing that y- you know, you, you, you do have your blind spots or your just, your areas of weaknesses, and that's okay 'cause we all do, right? But as long as you're willing to say, you know, "Okay, this might not be my area, but I trust the person whose area I know it is," then, then that's just such a great way to, to handle that and empower the next generation of leaders. So yeah, I love that that's your approach. [00:25:10] Dave Rosa: I also, you know, I, one other area that I think is also critical, and it goes back to what I said about individuals that I've met in larger companies, and I experienced this when I was in a larger company as well. You know, the focus becomes not making a mistake. And and, and it's because you know, the, these employees don't wanna make a mistake that's going to cost them their career in that company. So the safest thing to do is to do what your supervisor tells you to do, as opposed to take a chance and, you know, offer a different idea or a different concept. It's seen as risky and it's because there's this fear of making a mistake. I think it's smaller companies, especially in companies that I've run, you know, my, my philosophy is it's okay to make a mistake, but let's not make the same mistake more than once. I mean, they're, they're there to learn from. So let, let's, let's be smarter the, the second time, you know, because of that experience. But if people are afraid to make mistakes, you'll, you know, you're, you're never gonna get different ideas or different concepts you know, out, out, out amongst the group because of the fear of making a mistake. [00:26:26] Lindsey Dinneen: Mm-hmm. Right. Yeah, absolutely. Providing that, that opportunity and I, I know it's a bit of a cliche, but the, the idea of a safe environment at least to present those ideas and potentially counter opinions, and that's where creativity thrives is when you can iterate and bounce ideas off each other and, and come up with something that's, you know, you couldn't have done by yourself. Yeah, I love that approach. [00:26:50] Dave Rosa: Yeah. [00:26:51] Lindsey Dinneen: Yeah, so okay. This is, this is marvelous. I really appreciate all of this so far. But I'm gonna pivot the conversation a little bit just for fun. So imagine that you were to be offered a million dollars to teach a master class on anything you want. It could be within your industry, but it doesn't have to be. What would you choose to teach? [00:27:13] Dave Rosa: Yeah, this this doesn't fall under maybe necessarily, you know, a a class that you would see in a, a normal curriculum. But, you know, I-- it's, it's something that I've tried to talk to my own children about, and that's teaching them about being thankful for what they have and also, you know, giving back to others that are less fortunate. I-- you know, there's a saying that, that "comparison i- is the thief of joy." You know, the-- I, I think the human race in itself just has a way of always dwelling on, like, what we don't have as opposed to being, you know, thankful to God for all that we do have. And I, and I, I, you know, I, I really think that o- one of the things that I've tried to instill in, in, you know, my, my children, and now they're all grown, is you gotta be grateful for what, what you have, but you gotta find ways to find common ground with people and, and be sure to give back to others that, you know, haven't been as fortunate as you. I, I think that's, you know, what this world should be more focused on than, you know, all, all you hear about today is what we don't agree with and why this side or that political party, you know, is ruining the world. I think if we all focused a lot more of our energy on helping others you know, the, the world would be and this'll sound cliché, a much better place to live in. So if I could teach a course on instilling thankfulness and and the importance of helping others, that's what I would do [00:28:49] Lindsey Dinneen: Yeah. No, that I couldn't agree more. Gratitude and giving back are, are key and, and the world needs more of it, so I love that idea of a masterclass for sure. And how do you wish to be remembered after you leave this world? [00:29:06] Dave Rosa: Yeah, it's-- it kind of goes back to, you know, what my dad said to me, and that was you know, as, as a, a youngster and, and that is, you know, my, my passion and interest to really help others. Yeah, that sums it up the best. [00:29:23] Lindsey Dinneen: Yeah, absolutely. Okay, and final question: What is one thing that makes you smile every time you see or think about it? [00:29:33] Dave Rosa: I, I would say you know, there, there are people that will doubt you and put you down in your career and tell you why, you know, you'll never do this or you'll never do that. And I can honestly say I never thought, you know, I would ever stand in Nasdaq, you know, on Wall Street and take a company public. And, you know, the, the one thing I, I do kind of cherish is I've been able to do this twice, but the first time I remember standing on the stage before the activity started at Nasdaq and one of the people in the company said to me, they said like, "You know, you just had this smile, you know, on your face. You know, it looked like you were thinking of something." And I said, "Yeah, you know, I, I was thinking about all those times that people told me that, you know, I, you know, I would never be successful in my career," and you can define success in different ways, but it, it kind of made me feel good. It was the first time I think I really felt, you know, proud of myself that, "Wow, you know, I'm, I'm one of a very small percentage of people that have been fortunate enough to, to actually you know, take a company public." So, it always makes me smile. [00:30:52] Lindsey Dinneen: Yeah. Yeah, absolutely. Great answer, and that, that's a really cool moment to reflect back on. Well, Dave, this has been a great conversation. I so appreciate your willingness to, to talk with me today, but also to share about the, the incredible work that your company is doing and your heart for helping people from the very beginning of your childhood, and obviously a huge passion of yours throughout your life. And we are so honored to be making a donation on your behalf as a thank you for your time today to Opportunity International, which works to end global poverty by creating and sustaining jobs while also providing small business loans, savings, insurance, and training to more than 14 million people in the developing world. So thank you so much for choosing that organization to support, and thank you for everything that you're doing to change lives for a better world. [00:31:47] Dave Rosa: Well, thanks for having me on the show as well. [00:31:49] Lindsey Dinneen: Of course. [00:31:51] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

god ceo director ai marketing technology passion gratitude philadelphia italian pennsylvania mom wall street fda providing advancing nasdaq sir helping others product managers drexel university medtech stryker westinghouse boston scientific neurological disorders zimmer biomet electrode opportunity international jude medical

139 The Future of Parkinson's Care Is on Your Wrist

acast cork boston scientific

Play Episode Listen Later Aug 5, 2026 45:35

In our last episode, we featured a wearable device that uses gentle vibrations to help people manage Parkinson's symptoms and reduce anxiety. If you haven't listened yet, I encourage you to do so. It's a fascinating conversation about how something as simple as a vibrating wristband—BeechBand—may influence the brain in ways that help ease anxiety and tremors. Best of all, it's easy to use and fully refundable if it doesn't work for you in 100 days.. This episode also explores wearable technology, but with a very different purpose—one that could transform how we manage Parkinson's and partner with our healthcare teams. StrivePD, developed by Rune Labs, is an app that pairs with your Apple Watch to track movement, heart rate, sleep, and other important health data. It then provides easy-to-understand reports that highlight trends over time, giving you a clearer picture of how your Parkinson's is changing between doctor visits. Imagine arriving at your next appointment with objective, actionable information instead of relying on memory alone. That kind of insight can lead to more informed conversations and better care decisions. And this is only the beginning of what's possible with StrivePD. I thoroughly enjoyed my conversation with Rune Labs CEO Amy Gordon Franzen and learning about the future of digital health for Parkinson's. I think you'll find it both informative and inspiring. https://www.strive.group/ https://www.runelabs.io/post/strivepd-empowering-parkinsons-patients-with-personalized-insights amy@runelabs.io Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

care parkinson apple watches wrist dbs boston scientific deep brain stimulation rune labs

Otsuka's Voyxact Shines in Phase 3 Trial | Pharma and Biotech Daily

Pharma and BioTech Daily

Play Episode Listen Later Aug 5, 2026 4:47

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the latest scientific advancements, regulatory milestones, and strategic business maneuvers shaping the industry. One of the standout developments comes from Otsuka with their drug Voyxact, which has shown promising results in stabilizing kidney function decline in patients with immunoglobulin A nephropathy (IgAN). In a Phase 3 trial, patients exhibited kidney function comparable to that of healthy adults. IgAN is a challenging autoimmune condition often leading to end-stage renal disease. This advancement, leveraging a monoclonal antibody to target specific pathways, could mark a new era in managing this chronic kidney disease. In oncology, Jiangsu Alphamab Biopharmaceuticals has been making waves through strategic collaborations, securing deals worth $125 million upfront and potential milestone payments reaching over $2 billion. Their focus on developing antibody-drug conjugates (ADCs) using AI and machine learning underscores the promise of precision oncology. ADCs marry the targeting precision of antibodies with potent anti-cancer drugs, highlighting robust investment and confidence in these cutting-edge therapies. Merck & Co. continues to expand its financial outlook, driven by the success of its flagship drugs like Keytruda. This monoclonal antibody remains pivotal in cancer immunotherapy, while drugs like Winrevair and Lipfendra are broadening Merck's reach into cardiovascular health. This growth trajectory reflects a strategic push toward diversifying product lines and leveraging breakthrough therapies to maintain strong financial performance. Additionally, Merck's $10.8 billion acquisition of Prometheus Biosciences aims to expand their therapeutic portfolio with targeted biologics. Although mid-stage trials showed mixed results for their anti-TL1A antibody therapy, such acquisitions are pivotal in addressing unmet medical needs. On the regulatory side, Sanofi's MenQuadfi vaccine has achieved EU approval for use in infants as young as six weeks. This approval enhances preventive measures against invasive meningococcal disease in vulnerable populations, representing a significant public health advancement. In research methodologies, Sethera Therapeutics' collaboration with Receptor.AI is notable. By integrating AI-driven platforms for polymacrocyclic peptide discovery aimed at hard-to-drug targets, they're paving the way for overcoming traditional drug discovery challenges through computational tools. However, not all news is about progress. Jazz Pharmaceuticals faced a setback by withdrawing its label indication for Zepzelca after failing Phase 3 trials for small-cell lung cancer. This underscores the inherent risks in clinical development pathways. From a financial standpoint, BioNTech has adjusted its 2025 sales forecast downward due to waning global demand for COVID-19 vaccines—a reflection of the volatile vaccine markets post-pandemic peaks. Meanwhile, Pfizer's discontinuation of its Phase 2 GIPR antagonist for obesity illustrates strategic pivots within R&D pipelines as companies reassess priorities based on trial outcomes and market potential. Recent corporate strategies include Pfizer's ambitious cost-saving plan totaling $9.7 billion through 2029. Amid economic pressures and patent expirations looming on key products like Eliquis, Pfizer is optimizing operations to stay competitive. Speculation around a possible merger between Bristol Myers Squibb (BMS) and AstraZeneca has stirred interest. With both facing patent cliffs, this merger could rejuvenate portfolios—though the strategic benefits for AstraZeneca are still debated. On the technological front, advancements in cellular therapies promise to revolutionize medicine production at the cellular level, potentially enhancing patient outcomes through more personalized treatments. The regulatory landscape is also evolving. There's a growing call for streamlining Investigational New Drug applications under the FDA's Trialblazer initiative—crucial for accelerating clinical trials and bringing innovative therapies to market swiftly. Finally, initiatives such as Boston Scientific's restructuring efforts highlight challenges within the medical device sector as companies adapt to shifting market dynamics. Overall, these developments underscore an industry in motion where innovation and adaptation are key to navigating complex landscapes and advancing patient care globally. As we look ahead, these trends will likely continue shaping the future of pharmaceuticals and biotech in profound ways.Support the show

2026-07-30 What Now For Boston Scientific In Cork? Garda Weekend Travel Warning, Vanessa Feltz On Why She Loves Cork & More...

Cork's 96fm Opinion Line

Play Episode Listen Later Jul 30, 2026 144:19

Paul Byrne asks what the Boston Scientific restructuring means for Cork, hears Garda advice on Bank Holiday weekend travel, chats to Vanessa Feltz on reinventing herself and why she loves Cork. And more... Hosted on Acast. See acast.com/privacy for more information.

travel loves acast cork bank holiday garda boston scientific paul byrne vanessa feltz

What Does The Boston Scientific Announcement Mean For Cork?

Cork's 96fm Opinion Line

Play Episode Listen Later Jul 30, 2026 12:04

Paul talks to Donnchadh Ó Laoghaire TD who has concerns about the restructuring announcement yesterday Hosted on Acast. See acast.com/privacy for more information.

138 The Wearable That's Getting People Talking

Play Episode Listen Later Jul 27, 2026 38:40

Today we're talking about BeechBand, a wearable wellness device designed to support people living with neurological conditions, including Parkinson's disease. If you've spent any time in the Parkinson's community lately, you've probably heard the name. Carl Beech, the co-inventor and founder, seems to be everywhere sharing the story behind this innovative wearable. Friends of mine who have purchased a BeechBand rave about the results. Carl regularly appears in my Instagram feed, and when I attended the World Parkinson's Congress (WPC) in May, his booth was consistently packed with people eager to learn more. It's clear that the word is getting out, and BeechBand appears to be gaining real momentum. I have to admit—I became a believer myself. In this episode, Carl shares the origins of BeechBand, the personal story that inspired its creation, and how the device is designed to help people with Parkinson's. Listen in to discover what makes this wearable so intriguing. You just might become a believer, too. https://www.beechband.com/pages/about Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

friends parkinson wearable dbs getting people boston scientific deep brain stimulation carl beech

The Lead Episode 161: A Discussion of 20 Years: Clinical Outcome After Pulmonary Vein Isolation in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation

Play Episode Listen Later Jul 23, 2026 22:48

Recorded at EHRA 2026, this episode of The Lead features host Christopher Kowalewski, MD, in conversation with Christian Sohns, MD, and Pierre Jaïs, MD, about the journal article, 20 Years: Clinical Outcome After Pulmonary Vein Isolation in Patients With Symptomatic Drug-Refractory Paroxysmal Atrial Fibrillation. Together, they discuss the study's long-term clinical outcomes following pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation and explore the implications of two decades of follow-up. Learning Objectives: Review the long-term clinical outcomes reported after pulmonary vein isolation in patients with symptomatic drug-refractory paroxysmal atrial fibrillation. Discuss the implications of 20-year follow-up data for the treatment of patients undergoing pulmonary vein isolation. Examine how long-term outcome data may inform clinical decision-making for catheter ablation in paroxysmal atrial fibrillation. Host: Christopher Kowalewski, MD Guests: Christian Sohns, MD and Pierre Jaïs, MD Disclosures: C. Kowalewski No relevant disclosures C. Sohns No relevant disclosures P. Jaïs Ownership/Partnership/Prinicipal: inHEART Honoraria/Speaking/Consulting Fee: Biosense Webster, Inc., Boston Scientific, Medtronic

patients md isolation drug medtronic pulmonary vein atrial fibrillation boston scientific refractory symptomatic clinical outcomes paroxysmal

137 Learning to Grieve, Learning to Live

Manufacturers Alliance Podcast

Play Episode Listen Later Jul 21, 2026 33:00

For some reason, I've always been fascinated by grief and the grieving process. It seems to be everywhere—in the TV shows I watch, the podcasts I listen to, and the conversations I have with friends. Every one of us experiences grief, yet no two people grieve in exactly the same way. I've become curious about why that is and what we can learn from one another's experiences. That curiosity led me to attend a Support Group Leader session on grief at the World Parkinson Congress last May. One of the presenters was my friend, Karen McIntyre, who introduced an idea that really resonated with me: grief doesn't begin only when someone we love dies. For people living with Parkinson's, grief can occur every time they lose an ability that was once part of everyday life—driving a car, walking long distances, writing by hand, or even enjoying the smell of a favorite meal. What does that kind of grief look like? Is grieving the loss of an ability different from grieving the death of a loved one? Or do they share more similarities than we realize? To explore those questions, I invited Karen, who writes thoughtfully about grief on her Substack, to join me in interviewing an expert in grief and bereavement. Together, we discuss how grief affects all of us, why it takes so many different forms, and how people with Parkinson's and their care partners can better understand and navigate the losses that accompany the disease. This episode is truly for everyone because, at some point in our lives, we all grieve someone or something that has mattered deeply to us. https://clairebidwellsmith.com/ https://www.elegy.co/ https://substack.com/@inmyshoesmemoir Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

tv learning substack parkinson grieve dbs boston scientific deep brain stimulation world parkinson congress

Why Your Improvements Slowly Die

Play Episode Listen Later Jul 21, 2026 27:38

In this episode, Jeremiah Johnson, Global Lean Leader at Boston Scientific, joins Kirby to break down exactly why hard-won gains slowly disappear and what it takes to stop the backslide for good. Jeremiah brings a hard-earned perspective that goes far beyond the factory floor! ------------------------------ Unlock practical tools, training, and support to help your team improve. Manufacturers Alliance members get full access to our webinar library, digital courses, member pricing, and a statewide network of leaders who share what's working on the factory floor. Links: Attend a Community Group: https://www.mfrall.com/community/ Listen on Spotify: https://open.spotify.com/show/5orRRXkVgAkbAeUuCj1dP5 Listen on Apple: https://podcasts.apple.com/us/podcast/how-manufacturers-improve/id1677078610 Watch on YouTube: https://www.youtube.com/@UCfj2OPOknywMeVwzPJX7Ifw

spotify apple unlock improvements community groups jeremiah johnson boston scientific

Changing Physician Workflows Requires More Than Clinical Evidence: Interview with Sonex Health CEO Bob Paulson

Medsider Radio: Learn from Medical Device and Medtech Thought Leaders

Play Episode Listen Later Jul 20, 2026 51:03 Transcription Available

In this episode of Medsider Radio, we sat down with Bob Paulson, President and CEO of Sonex Health. Sonex's UltraGuideCTR device is a minimally invasive technology that enables ultrasound-guided carpal tunnel release procedures to be performed outside the surgical suite using local anesthesia, expanding patient access and reducing the cost of care.Before joining Sonex, Bob led multiple venture-backed medical device companies through commercialization, including NxThera, acquired by Boston Scientific, Restore Medical, acquired by Medtronic, and VentureMed Group. Earlier in his career, he held senior leadership roles at Medtronic, Advanced Bionics, and Endocardial Solutions, which was acquired by St. Jude Medical.In this interview, Bob explains how to build a reimbursement strategy before your first clinical study, drive physician adoption when introducing a new care pathway, and raise capital aligned with value inflection points. Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device founders and CEOs and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.And if you're ready to level up your medtech game, you should check out Medsider Courses — 8-week masterclasses covering topics like fundraising, M&A and exit planning, design and development, clinical and regulatory strategy, and commercialization.These courses, featuring hard-earned lessons from elite medtech CEOs, can be purchased individually or come free with our All-Access Pass.If you'd rather read than listen, here's a link to the full interview with Bob Paulson, which includes a link to ScottBot — an AI version of host Scott Nelson trained on every Medsider interview and playbook. Feel free to ask ScottBot any questions you'd like!KEY MOMENTS FROM THE INTERVIEW(03:19) - Bob's path from Medtronic to multiple medtech exits before joining Sonex (05:38) - Why 80% of eligible carpal tunnel patients avoid surgery — and how Sonex is changing that (11:11) - The reimbursement challenge that reshaped Sonex's clinical evidence strategy (19:07) - Reimbursement is a three-leg process: FDA, CPT, and payer coverage (22:07) - Reverse engineering your company from the exit you're trying to achieve (29:35) - How Sonex helped surgeons move carpal tunnel procedures out of the OR (39:06) - Sonex's "pitcher-catcher" approach to physician and patient adoption (41:59) - Bob's framework for choosing investors who can finance the entire journey, not just the next round

ceo health ai president entrepreneur healthcare startups ceos fda reverse physicians clinical requires regulatory workflows healthtech cpt medical devices medtech medtronic reimbursement paulson boston scientific scott nelson all access pass jude medical sonex medsider radio

Episode 160: A Discussion of Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study

Play Episode Listen Later Jul 16, 2026 14:08

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Kenneth Ellenbogen, MD, FHRS, about the journal article, Real-time smartphone alerts during atrial fibrillation episodes with implantable cardiac monitors and wearable devices: SMART-ALERT study. Together, they discuss the study findings and explore the use of real-time smartphone alerts in conjunction with implantable cardiac monitors and wearable devices during atrial fibrillation episodes. Learning Objectives Review the design and key findings of the SMART-ALERT study evaluating real-time smartphone alerts during atrial fibrillation episodes. Discuss the use of implantable cardiac monitors and wearable devices for real-time detection and notification of atrial fibrillation episodes. Explore the potential clinical implications of integrating smartphone alerts with cardiac monitoring technologies. Host: Michael S. Lloyd, MD, FHRS Guests: Tina Baykaner, MD, MPH Kenneth A. Ellenbogen, MD, FHRS Disclosures: M. Lloyd · Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other T. Baykaner · Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific · Research: NIH, Boston Scientific K. Ellenbogen · Honoraria/Speaking/Consulting Fee: American College of Cardiology, Heart Rhythm Society, Boston Scientific, Medtronic, Inc., Abbott · Royalty Income: Wiley-Blackwell, Elsevier

real explore study md smartphones mph real time cardiac cardiology johnson johnson alerts monitors medtronic atrial fibrillation elsevier boston scientific implantable wearable devices heart rhythm society

136 Intimacy: Staying Connected Through Change

intimacy parkinson staying connected dbs boston scientific deep brain stimulation

Play Episode Listen Later Jul 14, 2026 31:47

Intimacy is one of the most important topics we can discuss, yet it's also one that I've hesitated to bring to this podcast. For many of us, it's still considered a taboo subject. But the reality is that intimacy and relationships are an important part of life for everyone—and they can become even more important, and sometimes more challenging, for people living with Parkinson's disease and their care partners. Since I'm certainly not the expert on this topic—and I'll admit it makes me a little uncomfortable—I've invited someone who is. Dr. Kelly Rees is a licensed sex therapist in private practice who has a remarkable ability to discuss intimacy in an open, approachable, and judgment-free way. In our conversation, she explains why nurturing intimacy is so important throughout the Parkinson's journey, offers practical insights for navigating the changes that can occur, and reminds us that connection comes in many forms. So, whether you're living with Parkinson's, supporting someone who is, or simply interested in strengthening your relationships, I think you'll find this conversation both informative and reassuring. Let's listen https://drkellyrees.com/ https://www.aasect.org/referral-directory Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

The Lead Episode 159: A Discussion of Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm

Play Episode Listen Later Jul 9, 2026 14:34

Recorded at EHRA 2026, this episode of The Lead features host Michael S. Lloyd, MD, FHRS, in conversation with Tina Baykaner, MD, MPH, and Prashanthan Sanders, MBBS, PhD, FHRS, about the journal article, Atrial Mechanical Contraction Predicts Cerebrovascular Risk in Patients With Transthyretin Amyloid Cardiomyopathy and Sinus Rhythm. Together, they discuss the study findings and explore the relationship between atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy who are in sinus rhythm. Learning Objectives: Review the key findings of the study examining atrial mechanical contraction and cerebrovascular risk in patients with transthyretin amyloid cardiomyopathy and sinus rhythm. Discuss the association between atrial mechanical contraction and cerebrovascular risk in this patient population. Explore the potential clinical implications of assessing atrial mechanical function in patients with transthyretin amyloid cardiomyopathy. Host: Michael S. Lloyd, MD, FHRS Guests: Tina Baykaner, MD, MPH Prashanthan Sanders, MBBS, PhD, FHRS Disclosures: M. Lloyd Honoraria/Speaking/Consulting Fee: Medtronic, Boston Scientific, Other T. Baykaner Honoraria/Speaking/Consulting Fee: Volta Medical, Medtronic, Pacemate, Johnson & Johnson, Abbott Medical, Boston Scientific Research: NIH, Boston Scientific P. Sanders Honoraria/Speaking/Consulting Fee: Boston Scientific, Abbott Medical Other Financial Relationships: Medtronic PLC, Pacemate, CathRx Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical

135 Improving Balance with Parkinson's: What You Need to Know

balance improving loud parkinson moves dbs mahjong boston scientific deep brain stimulation pwr

Play Episode Listen Later Jul 1, 2026 41:18

I have told this story many times. After my diagnosis, my doctor wanted me to learn the "Big and Loud" program or LSVP. The physical therapist at the outpatient clinic saved my life. He told me I was going to live a long life and how to exercise Big. He told me to do something for my brain like play Mahjong. I followed his directions. I go to physical therapy every year to continue to work on balance, posture and gait. I think a good PT is a key member of your medical team. Physical therapy is one of the most powerful tools available for living well with Parkinson's disease, and in this episode, Dr. Jennie Allex explains why movement is truly medicine. As a board-certified neurologic physical therapist and Parkinson's specialist, Jennie shares how targeted exercise can help people maintain mobility, improve balance, reduce fall risk, and preserve independence throughout every stage of the disease. In this episode, we are focused on one issue which is very important to address – balance. It turns out there is a lot going on in your brain and body to keep you upright. Jennie discusses how Parkinson's affects the three systems that work together in order to prevent falls. She emphasizes how important it is to get an assessment from a qualified PT so you get the best treatment to improve your balance. The conversation explores practical strategies for balance while highlighting the importance of consistent exercise between therapy visits. Jennie explains how specialized Parkinson's programs, including evidence-based approaches such as PWR!Moves® and other Parkinson's-specific interventions, help retrain movement and build confidence. Whether you're newly diagnosed, have been living with Parkinson's for years, or care for someone with the disease, this episode provides practical, encouraging guidance on how physical therapy can help you move better, stay stronger, and continue living to the fullest. https://www.dailydosepd.com/ https://theparkinsonsfitnessproject.com/ Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches

Unglaubliche erste 6 Monate und der deutsche Median-Schock

Alles auf Aktien

Play Episode Listen Later Jul 1, 2026 23:54 Transcription Available

In der heutigen Folge sprechen die Finanzjournalisten Nando Sommerfeldt und Holger Zschäpitz über den Circle-Schock, die Abivax-Erleichterung und Ernüchterndes von Nike. Außerdem geht es um Siemens Energy, Citigroup, Siemens, Bank of America, Abivax, SMA Solar, Jefferies, Circle, Visa, BlackRock, Alphabet, Coinbase, Cognizant, Intuit, Charter Communications, Boston Scientific, Oracle, Trimble, Leidos, UBS, OHB, iShares MSCI World Momentum Factor Advanced ETF (WKN: A3CUJS), iShares Edge MSCI World Quality Factor ETF (WKN: A12ATE), Vanguard FTSE All-World High Dividend Yield ETF (WKN: A1T8FV), iShares Edge MSCI World Minimum Volatility ETF (WKN: A1J781). Und hier der Podcast-Link zur Cash-Burners Lilium-Story: https://open.spotify.com/episode/0aFq46uMdsSDB7gRA1IXri?si=E66fBk32QEKoKAmgQRSp4g&nd=1&dlsi=e4be74d32e4148ff Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Ep. 659 Combination Therapy for Hepatocellular Carcinoma with Dr. Beau Toskich and Dr. Lingling Du

Play Episode Listen Later Jun 30, 2026 44:44

How do you safely combine locoregional and systemic therapies to treat hepatocellular carcinoma (HCC) when traditional guidelines suggest your hands are tied? In this episode of the 2026 HCC Creator Weekend™, medical oncologist Dr. Lingling Du (Ochsner Health) and interventional radiologist Dr. Beau Toskich (Mayo Clinic Florida) join Dr. Tyler Sandow to break down patient selection, timing strategies, and the practical application of clinical trial outcomes when integrating Y90 radioembolization and immunotherapy in HCC management. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction01:48 - Two HCC Cases03:31 - Disease Progression on Combination Therapy07:05 - Alternatives After Immunotherapy Failure09:09 - Salvage with Ablative Y9013:41 - Mechanism of Immunotherapy15:43 - EMERALD-1 and LEAP-01220:52 - Adverse Events with Combination Therapy27:21 - Treatment Timing and Sequencing28:48 - Case: Borderline BCLC B33:48 - Case: BCLC C with Portal Vein Thrombus37:06 - Raising the Survival Tail40:11 - Final Thoughts and Closing Remarks --- More about this episode The physicians highlight how selective local treatment can achieve complete responses and salvage cases with aggressive disease. They emphasize that treatment based on anatomical and biological phenotype may yield better results than strictly adhering to rigid staging categories, while acknowledging the challenges of managing microscopic disease and unpredictable long-term tumor behavior. Dr. Du and Dr. Toskich also note that selecting the right combination regimens requires balancing aggressive tumor kinetics against the patient's baseline liver function, pointing out that well-tolerated regimens like STRIDE are often easier to pair with Y90 than checkpoint or VEGFR inhibitors that alter tumor blood flow. While recent TACE-immunotherapy trials (EMERALD-1 and LEAP-012) may be confounded by patient heterogeneity, the physicians observe that a distinct subset of patients achieves durable, long-term remission, effectively raising the survival tail for an otherwise incurable population. Ultimately, they conclude that cross-specialty education and leaning into the expert intuition of a multidisciplinary team are essential for securing the best outcomes for patients with intermediate and advanced HCC. --- Resources Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)https://clinicaltrials.gov/study/NCT03298451 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave150)https://clinicaltrials.gov/study/NCT03434379 Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trialhttps://doi.org/10.1016/S0140-6736(25)00403-9 Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 studyhttps://doi.org/10.1016/S0140-6736(24)02551-0 Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 studyhttps://doi.org/10.1016/S0140-6736(24)02575-3 --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

raising treatments leap final thoughts emerald stride mechanism salvage hcc boston scientific adverse events hepatocellular carcinoma tace disease progression combination therapy atezolizumab vegfr y90 backtable

Learn How Great Leaders Become Great Speakers | John Bates | Ep. 173

I See What You're Saying

Play Episode Listen Later Jun 24, 2026 54:08

What if the reason your best ideas keep falling flat has nothing to do with the quality of the idea?In this episode, Michael Reddington sits down with John Bates, a globally recognized leadership and executive communications coach who has worked with organizations including NASA, Intuit, and Johnson and Johnson. John has delivered multiple TED Talks, coached executives and leaders on every continent, and built a career around one core conviction: communication is not logical. It is biological.This conversation will fundamentally change how you think about every high-stakes conversation you walk into. John breaks down why the ancient part of your brain makes decisions before your logical brain even gets a vote, why trying to establish your credibility usually destroys it, and why the most powerful thing a speaker can do is stop talking about themselves.John unpacks the neuroscience behind why people say yes, yes, yes and then no, how to build emotional credibility before you say a single persuasive word, and the difference between vulnerability that connects and vulnerability that costs you. If you lead people, sell ideas, or speak in front of any audience at all, this episode will give you a new framework for what it actually means to land your message where it counts.What You'll Learn in This EpisodeWhy communication is biological and why logic alone will almost never win a high-stakes conversationHow the paleomammalian brain makes decisions before the logical brain even registers themWhy the yes, yes, yes, no pattern in sales and negotiations is not a lie but a missing emotional connectionWhat emotional credibility is, why it needs to come first, and how to establish it fastHow insightful vulnerability builds trust faster than any credential or accomplishmentWhy your credibility is already established before you walk into the room and trying to prove it only hurts youThe difference between curating for your audience versus dumping everything you know on themWhy saying "I told you so" is proof you failed to communicate, not proof you were rightHow to reframe public speaking anxiety by shifting your attention from yourself to the people you are servingWhy the best ideas, candidates, and products often lose because communication broke down, not because they were wrongChapters(00:00) Why Communication Is Biological, Not Logical(04:24) How the Paleomammalian Brain Makes Decisions Before You Do(08:08) The Yes Yes Yes No Problem and What It Really Means(13:25) What Emotional Credibility Is and Why It Has to Come First(16:59) Origin Stories and the Power of Insightful Vulnerability(22:06) "Don't Insult the Listening" and the Lesson of Trusting Your Audience(26:56) Why Communication Is a Function of Leadership(28:33) Taking Responsibility for What People Hear, Not Just What You Say(33:05) How to Make the Complicated Simple by Curating, Not Dumping(41:37) How to Beat Public Speaking Anxiety by Serving Instead of PerformingAbout the GuestJohn Bates is an executive leadership communications coach, keynote speaker, and entrepreneur who has spent over 15 years helping leaders, teams, and organizations communicate in ways that actually move people. His clients include NASA, Intuit, Johnson and Johnson, Boston Scientific, and Accenture. He has delivered multiple TED Talks, been featured in media around the world, and built a global practice around the idea that great communication is not about saying the right things. It is about making sure the right things land. John coaches one on one, works with small and large teams, and produces free training content through his newsletter and website.Links and ResourcesJohnBates.com - https://www.johnbates.comExecutiveSpeakingSuccess.com - https://www.executivespeakingsuccess.comJohn Bates | LinkedIn - https://www.linkedin.com/in/johnbatesSponsor Links:InQuasive: http://www.inquasive.com/Humintell: Body Language - Reading People - HumintellEnter Code INQUASIVE25 for 25% discount on your online training purchase.International Association of Interviewers: Home (certifiedinterviewer.com)Podcast Production Services by EveryWord Media

Ep. 657 Advanced Techniques in Y90 Cancer Treatment with Dr. Beau Toskich and Dr. Juan Gimenez

ai drawing transformational medtech resources connect boston scientific board advisor james corbett

Play Episode Listen Later Jun 23, 2026 51:37

What do you do when Y-90 doesn't deliver the results you expected? In this episode of the 2026 HCC Creator Weekend™, host Dr. Tyler Sandow is joined by Drs. Beau Toskich and Juan Gimenez to discuss the technical challenges and troubleshooting strategies that can make or break a Y-90 radioembolization case. Together, they explore innovative approaches like the PREDATr technique, share tips for reducing complications, and offer guidance on optimizing outcomes for patients with complex liver tumors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction04:24 - Treatment Nonresponse Troubleshooting06:12 - Navigating Y90 Through Replaced Arteries09:09 - Mitigating Vasospasm in Embolization13:31 - What is ‘PREDATr'?21:12 - Dual Balloon Microcatheter System23:37 - Gelfoam Techniques and Application26:06 - Embolization Agents Preferences36:16 - Concerns with Cystic Artery Treatment and Biliary Stents42:15 - Prophylactic Antibiotics 44:29 - Utilizing High Lung Shunts49:28 - Wrap Up and Credits --- More about this episode The conversation begins with case-based examples of HCC radioembolization, focusing on how to assess treatment response and troubleshoot nonresponsive cases. They discuss how to interpret SPECT findings, identify missed tumor supply with cone-beam CT, and overcome obstacles such as vasospasm, extrahepatic feeders, and challenging arterial anatomy. They introduce the PREDATr technique (proximal radioembolization enabled by distal angiozone truncation) and explain how tools like gelfoam, balloons, and retrievable coils can preserve healthy liver tissue and improve microsphere delivery. The episode also addresses managing biliary stents, using antibiotic prophylaxis, and strategies for handling high lung shunts, making it a practical resource for anyone navigating the complexities of Y-90 treatment. --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

treatments concerns drs wrap up cancer treatment gimenez hcc boston scientific spect backtable

Creating the Future of MedTech Through Purpose with James Corbett, transformational MedTech CEO and Board Advisor

Outcomes Rocket

Play Episode Listen Later Jun 17, 2026 32:17

MedTech innovation succeeds when bold ideas are matched with disciplined execution, strong teams, and a clear purpose. In this episode, James Corbett, transformational MedTech CEO and Board Advisor, joins Saul to share the leadership lessons, operating principles, and industry changes that have shaped his decades-long career. Drawing on experience leading companies including Boston Scientific, ev3, Alphatec Spine, CathWorks, and AVITA Medical, Jim explains why people and purpose are the foundation of lasting success in healthcare. He discusses the future of MedTech, including the creation of new clinical categories, the importance of operational excellence, and the growing role of AI in leadership and business transformation. Jim also shares why many organizations are underutilizing AI, how his AI command center captures decades of operating knowledge, and why great people remain the ultimate competitive advantage. Tune in and learn how purpose-driven leadership, operational discipline, and AI-enabled execution can help shape the next generation of MedTech innovation! Resources: Connect with and follow James Corbett on LinkedIn. Explore Jim Corbett AI!

Ep. 653 Radiation Lobectomy Techniques & Downstaging for HCC with Dr. Beau Toskich and Dr. Chris Malone

Play Episode Listen Later Jun 9, 2026 45:01

How can targeted liver radiation unlock surgical or transplant options for tough hepatocellular carcinoma (HCC) cases? In this episode of BackTable 2026 HCC Creator Weekend™ host Dr. Kavi Krishnasamy is joined by interventional radiologists Dr. Beau Toskich and Dr. Chris Malone to explore how downstaging and radiation lobectomy with Y-90 are creating new surgical and transplant opportunities for patients with limited future liver remnants. They discuss Y-90's role as a “test of time” for tumor biology, strategies to prevent post-hepatectomy liver failure, and the ongoing challenge of recurrence even after R0 resection in cirrhotic livers. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Sirtex and Boston Scientific. --- Timestamps 00:00 - Introduction01:31 - Rad Lobectomy Goals and Case Discussion06:09 - Selective vs Lobar Dosing07:51 - PVE Versus Y9009:35 - Downstaging to Transplant13:03 - Patient Selection Factors19:22 - Radseg vs. Lobar Strategy22:12 - Percent Liver Treated Debate26:38 - Particle Density and Catheter Bias28:04 - Downstaging Evidence MERIT LT36:20 - Operating After Y9041:25 - Hypertrophy Timing and Readiness43:03 - Wrap Up --- More about this episode The discussion features a case of massive right-lobe HCC in a non-cirrhotic patient, with stepwise Y-90 dosing and selective retreatment leading to complete response and marked liver hypertrophy. The doctors compare radiation lobectomy with portal vein embolization (PVE), explore dosimetry advances from studies like DOSISPHERE and MERITS-LT, and stress the importance of careful mapping and patient selection. Additional topics include the pros and cons of different downstaging methods, functional imaging to assess risk, the impact of lab values and portal hypertension, and the practicalities of timing surgery after Y-90. --- Resources Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trialhttps://jnm.snmjournals.org/content/early/2024/01/10/jnumed.123.266211 Downstaging hepatocellular carcinoma before liver transplantation: A multicenter analysis of the "all-comers" protocol in the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) consortiumhttps://pubmed.ncbi.nlm.nih.gov/37532179/ --- BackTable Vascular & Interventional (VI) is the go-to podcast for interventional radiologists, vascular surgeons, and interventional cardiologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

reduction radiation selective pve hcc boston scientific r0 chris malone lobectomy backtable

Ep. 651 Radioembolization Workflow: Insights & Best Practices with Dr. Nima Kokabi and Dr. Kirema Garcia-Reyes